Ammar Adam

Cambridge Scientific (United States) — United States

Medicine · Health Sciences

14h-index1.3kcitations93works1.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(24), Mathematical Biology Tumor Growth(22), Chromatin Remodeling and Cancer(19), Renal cell carcinoma treatment(16), Protein Degradation and Inhibitors(15)

Publications92 total

CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies
Journal of Hematology & Oncology·2026Open Access
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025· 1 citedOpen Access
Author response: Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025Open Access
Author response: Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025Open Access
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025Open Access
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
Journal of Medicinal Chemistry·2025· 16 cited
Abstract B024: Leveraging synthetic lethality across EP300-mutant solid cancers through selective CBP degradation
Molecular Cancer Therapeutics·2024
Reviewer #3 (Public Review): Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024Open Access
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024Open Access
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024· 1 citedOpen Access
Reviewer #2 (Public Review): Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024Open Access
Reviewer #1 (Public Review): Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024Open Access
Abstract 6067: Identification of selective CBP degraders with robust preclinical PK, PD, efficacy and safety across solid tumor indications
Cancer Research·2024· 1 cited
Abstract 6064: Discovery of potent and selective EP300 degraders with anti-cancer activity
Cancer Research·2024· 2 cited
Abstract 7185: Long acting injectable FHD-609 micro-suspension: A potent BRD9 degrader with comparable efficacy, reduced frequency of dosing in preclinical models
Cancer Research·2024
Abstract A056: Treatment with dual BRG1/BRM (SMARCA4/2) inhibitor FHD-286 ablates tumor-associated androgen response elements (AREs) in prostate cancer
Molecular Cancer Therapeutics·2023· 1 cited
Abstract A049: Investigation of FHD-609, a potent degrader of BRD9, in preclinical models of acute myeloid leukemia (AML)
Molecular Cancer Therapeutics·2023· 5 cited
Abstract A013: Leukemic stem cell differentiation visible at single-cell resolution in AML patients treated with BRG1/BRM inhibitor FHD-286
Molecular Cancer Therapeutics·2023
Abstract A060: Discovery of potent and selective EP300 degraders with anti-cancer activity
Molecular Cancer Therapeutics·2023
Abstract A058: Investigating the molecular role of BRD9 in synovial sarcoma
Molecular Cancer Therapeutics·2023
page 1 of 5Next →

Frequent Co-authors

Alwin G. Schuller(22), Stephen E. Fawell(19), Michael Zinda(18), Eric T. Gangl(13), J. Paul Secrist(13), Edward J. Hennessy(13), Terry Macintyre(13), Jamal Saeh(13), Kate F. Byth(13), Justin Cidado(12), Francis D. Gibbons(12), Edwin Clark(12), Paula Lewis(12), Gareth P. Gregory(11), Ricky W. Johnstone(11), Nancy Su(11), Srividya B. Balachander(11), William McCoull(11), Shenghua Wen(11), Barry R. Davies(11)